Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311)

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. Zanzalintinib (XL092) is an investigational, oral, multi-targeted tyrosine kinase inhibitor (TKI) being developed by Exelixis for various advanced cancers, blocking pathways like VEGFR, MET, and TAM kinases (AXL, MER, TYRO3) involved in tumor growth, spread, and resistance to therapy. Everolimus is already known in NET circles.

This study has 25 locations, most in US but also in Puerto Rico and London, England. See inside clinical trials document below.

Always check the exclusion and exclusion criteria (see inside) to see if this trial fits you. Also discuss with your specialist. Clinical trial contact inside.

Click below to read the clinical trials document – Click here

Thanks for reading